Mild, Moderate, and Severe Depression: How Severity Changes Care
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Mild, moderate, and severe depression describe the intensity and consequences of a depressive episode. Clinicians use these distinctions to plan treatment, determine the urgency of follow-up, and decide what level of support someone needs. A person with mild depression may still meet diagnostic criteria for major depressive disorder; someone with severe depression may struggle with eating, getting out of bed, making decisions, maintaining basic safety, or functioning at work or home. The label describes the current clinical picture rather than the person's character, resilience, or prognosis.
Severity is assessed through symptoms, duration, distress, daily functioning, clinical history, and safety. Questionnaires contribute useful information, but a questionnaire score alone cannot establish a diagnosis or assign a complete severity assessment. Evidence-based adult treatment options range from structured psychological support and psychotherapy to antidepressants, combined treatment, specialized services, and selected interventions for complex or life-threatening episodes. See the NIMH depression overview, NICE depression guideline, and VA/DoD guideline.
This guide explains what mild, moderate, and severe depression mean clinically, why a person's level of functioning matters, how treatment usually changes with severity, where screening tools fit, and when the need for care becomes urgent. For the complete diagnostic process, see Depression Diagnosis: What a Clinical Evaluation Includes.
I. The essential distinction: severity guides care
Depression severity is a clinical judgment about the present episode. The same depressive disorder can involve episodes of different intensity over time. Symptoms can improve, recur, or change in character; therefore severity should be reassessed during treatment and whenever functioning or safety changes. The World Health Organization's ICD-11 diagnostic descriptions recognize mild, moderate, and severe depressive episodes, while NICE NG222 organizes adult treatment around “less severe” and “more severe” depression.
In everyday terms, mild depression often means a recognizable depressive syndrome with some capacity to continue ordinary activities, though with effort or reduced effectiveness. Moderate depression generally involves broader symptoms and more noticeable interference with work, studies, relationships, self-care, or household responsibilities. Severe depression can produce major impairment, profound slowing or agitation, inability to sustain essential routines, and sometimes psychotic features. These are illustrative patterns, not a scoring system that readers can apply to themselves.
Severity is only one clinical dimension. A person with fewer depressive symptoms may still need immediate help for suicidal thoughts, inability to remain safe, a rapidly changing mental state, or severe medical vulnerability. The NICE assessment recommendations require direct attention to suicidal ideation and intent, prior episodes, past treatment, comorbidity, and circumstances that affect care.
II. What mild, moderate, and severe depression mean
1. Mild depression
A mild depressive episode involves clinically significant symptoms that are relatively limited in intensity or impact compared with more severe episodes. Low mood or loss of interest may coexist with sleep disturbance, reduced energy, pessimistic thoughts, concentration difficulties, or changed appetite. Someone may continue to attend work or school yet take longer to complete tasks, withdraw from friends, or stop enjoying familiar activities.
Mild describes current symptom burden and impairment. It does not mean the distress is imaginary or that the person should manage alone. Major depressive disorder can be diagnosed with a mild current episode when the full diagnostic criteria are met; symptoms that remain below the threshold for a depressive disorder require a different assessment. Clinicians distinguish these presentations through an interview rather than through the word “mild” alone. See the WHO classification and NIMH depression description.
2. Moderate depression
Moderate depression generally involves more pervasive symptoms, greater interference with functioning, or both. A person might attend some obligations but miss others, struggle to organize daily tasks, lose motivation and concentration, withdraw socially, or find ordinary decisions exhausting. The clinical picture can contain substantial guilt, hopelessness, sleep disruption, fatigue, or loss of pleasure.
Moderate depression deserves active treatment planning. The clinician discusses the person’s preferences, previous responses to therapy or medication, existing health conditions, availability of care, and the relative benefits and burdens of different options. Moderate episodes can be treated successfully without assuming a single mandatory treatment for every patient. NICE NG222 and the VA/DoD guideline emphasize evidence-based choices and shared decisions.
3. Severe depression
Severe depression is characterized by particularly intense or extensive symptoms, pronounced functional impairment, or both. Everyday life may become difficult to sustain. Some people develop extreme psychomotor slowing, marked agitation, major disturbances of sleep and appetite, or inability to care for basic needs. Psychotic symptoms such as delusions or hallucinations can occur in some depressive episodes and demand specialist evaluation.
Severe depression usually calls for more intensive assessment, closer monitoring, and prompt access to appropriate treatment. Specialist psychiatric care or a higher level of support may be necessary when symptoms are difficult to manage in routine outpatient care, when basic self-care has deteriorated, or when safety cannot be maintained. NICE NG222 addresses severe, psychotic, and potentially life-threatening presentations, including circumstances in which electroconvulsive therapy is considered.
III. Clinical severity versus the number of symptoms
Two people may endorse similar numbers of depressive symptoms but have very different clinical needs. Symptoms vary in intensity and pattern: repeated early-morning waking differs from near-total inability to sleep; reduced appetite differs from inadequate food intake; difficulty concentrating differs from being unable to make routine decisions. Duration, distress, co-occurring illness, support, occupational demands, and the ability to perform necessary tasks further alter the assessment.
Functional impairment is central. Clinicians ask whether a person can maintain hygiene, obtain food, care for dependents, keep essential appointments, manage medications, study or work, communicate with others, and make safe decisions. They also ask what these tasks cost the person in effort. A patient who looks competent at work may still experience profound distress, disengagement, or collapse outside work. Apparent productivity is an unreliable substitute for clinical assessment. NICE specifically includes personal and social functioning in recognition and assessment.
The timing and course matter as well. A first episode following a major stressor, a recurrent episode after years of remission, and persistent depressive symptoms over a long period may call for different follow-up plans. A severe current episode is not equivalent to treatment-resistant depression, which concerns insufficient response to adequate treatments and requires a separate review of diagnosis, duration, dosage, adherence, and treatment history. See the VA/DoD guideline.
IV. Screening scores: what PHQ-9 categories do and do not tell you
The Patient Health Questionnaire-9, or PHQ-9, is often used to record symptom frequency over the previous two weeks. The commonly cited conventional score bands are 0–4 for minimal symptoms, 5–9 for mild symptoms, 10–14 for moderate symptoms, 15–19 for moderately severe symptoms, and 20–27 for severe symptoms. These are bands on a symptom questionnaire. Their clinical meaning depends on diagnostic assessment, functional impairment, context, and safety. The original validation study established the instrument as a measure of depressive symptom severity, not as a substitute for a complete diagnostic interview: Kroenke, Spitzer, and Williams (2001).
The difference between questionnaire categories and guideline categories is particularly important. NICE NG222 uses a two-group treatment framework: less severe depression includes subthreshold and mild presentations, and more severe depression includes moderate and severe presentations. In that guideline, a PHQ-9 threshold of 16 was used as an indicator when developing recommendations. It is a guideline-specific decision threshold; it does not redefine the original PHQ-9 score bands, establish a universal diagnosis, or mean that a score of 15 is clinically safe while a score of 16 is inherently dangerous. NICE definitions and recommendations.
Scores can support follow-up by showing whether reported symptoms are changing. A single score cannot explain why symptoms are present, exclude bipolar disorder or medical causes, detect all psychotic experiences, or fully assess suicidal risk. A reported thought of death or self-harm requires individual follow-up irrespective of the total. Questionnaires are most useful when interpreted alongside a conversation about the person's actual experience and functioning. NICE; Kroenke et al..
V. How clinicians determine the level of care
A complete assessment begins by establishing the presence, timing, and impact of depressive symptoms and identifying whether the clinical picture fits a major depressive episode, another depressive condition, a medical or substance-related cause, or a different psychiatric disorder. It also includes a history of mania or hypomania, which can change both the diagnosis and treatment decisions. The NIMH overview and VA/DoD guidance provide the foundation for this evaluation.
A practical assessment considers symptom severity, loss of functioning, duration and recurrence, sleep and nutrition, existing physical health conditions, alcohol and other substance use, medication effects, exposure to major stressors, available support, and previous treatment. The clinician asks about suicidal thoughts directly and evaluates urgency on the basis of individual findings, not just the mild/moderate/severe label.
Severity should also be considered in relation to what the person can realistically do. Attending weekly therapy, using a workbook, following a medication plan, traveling to appointments, or participating in group treatment all require some capacity and support. A person with substantial impairment may need help with access, scheduling, family involvement when appropriate, transportation, or more intensive services. These considerations affect whether an otherwise effective treatment is practically feasible. NICE care-delivery guidance.
VI. Treatment for mild and other less severe depression
For an adult with a new episode of less severe depression, clinicians commonly discuss guided self-help based on established psychological approaches, structured psychological treatment, behavioral activation, group or individual psychotherapy, and exercise-based interventions. A suitable choice depends on the patient's preferences, previous experience, current ability to engage, costs, availability, and the evidence for that option. Guided self-help is structured support that usually draws on cognitive behavioral or behavioral activation principles, sometimes with a practitioner helping the person apply them. NICE NG222, section 1.5.
When someone with less severe depression prefers not to start treatment immediately or is already improving, an agreed period of active monitoring can be appropriate. This means discussing symptoms and risks, making it clear how to access help, and arranging a further assessment, normally within two to four weeks under NICE guidance. Active monitoring is a deliberate care plan with follow-up; it should not become indefinite abandonment. NICE recommendation 1.5.1.
Antidepressants are an available option, but guidelines differ in how they frame first-line use for less severe cases. NICE advises against routinely offering an antidepressant first-line for less severe depression unless it is the informed preference of the person. U.S. treatment planning also weighs prior episodes, personal preference, access to psychotherapy, past medication response, tolerability, and comorbidities. A patient who has improved with a particular treatment in the past may reasonably discuss that history in making a new plan. NICE NG222; NIMH.
Daily routines, activity, sleep regularity, social connection, and movement may support recovery and reduce secondary difficulties. They are best understood as parts of a broader individualized plan and should not be presented as guaranteed cures or a substitute for indicated professional treatment. Someone whose symptoms persist, worsen, or interfere increasingly with functioning needs reassessment and possibly a change in treatment intensity. NIMH.
VII. Treatment for moderate depression
Moderate depression more often leads to a discussion of formal psychotherapy, antidepressant medication, or their combination. Cognitive behavioral therapy, behavioral activation, interpersonal psychotherapy, and other structured, evidence-based psychological approaches are reasonable choices according to circumstances and available expertise. Research supports CBT as an effective treatment for adult depression across many trials, though individual response varies and not every comparison produces the same effect size. Cuijpers et al. (2023), meta-analysis of 409 trials.
Medication may be considered when symptoms are persistent or substantially impairing, when a patient prefers medication, when prior response supports it, or when the broader clinical picture favors pharmacotherapy. Selective serotonin reuptake inhibitors are frequently chosen initially for adults because of their established efficacy and generally acceptable tolerability; selection should incorporate contraindications, interactions, adverse effects, previous response, pregnancy-related considerations when relevant, and patient preference. Medication typically needs several weeks for a meaningful assessment of benefit, and early monitoring is important. NICE NG222; VA/DoD.
Combination treatment can be a suitable starting choice, especially when symptoms are more burdensome, prior single-modality care has not worked, or a patient values both approaches. NICE lists combined individual CBT and an antidepressant, individual CBT, other psychological therapies, and antidepressant treatment among options for more severe depression. The ranking of options in that guideline reflects both clinical effectiveness and cost-effectiveness in its health system; an individual treatment decision still requires shared discussion. NICE NG222, section 1.6.
Treatment intensity also concerns access and monitoring. Two people classified as moderately depressed may need different plans because one has a supportive home environment and a flexible schedule while the other has significant medical illness, unstable housing, or substantial caregiving responsibilities. Effective care is adapted to these circumstances instead of being selected mechanically from the severity label.
VIII. Treatment for severe depression
Severe depression calls for timely clinical assessment and an active treatment plan. Depending on the presentation, treatment may include an antidepressant, a structured evidence-based psychotherapy, their combination, specialist psychiatric involvement, and practical support sufficient to maintain essential activities. When a person cannot manage basic needs, has psychotic symptoms, or faces serious safety concerns, the question becomes whether routine outpatient treatment provides adequate support. NICE NG222; VA/DoD.
Combined medication and psychotherapy is often considered in more severe cases because medication and therapeutic work may address different aspects of the illness. Psychotherapy can target behavioral withdrawal, entrenched negative thinking, interpersonal problems, and approaches to relapse prevention, while medication may help reduce the depressive syndrome. The relative contribution and tolerability of each intervention vary, making regular collaborative reassessment essential. NICE NG222; Cuijpers et al..
Some severe episodes involve psychotic symptoms. Beliefs of catastrophic guilt, ruin, or bodily destruction, or hallucinations occurring in the context of depression, require specialist assessment. Psychotic depression can call for coordinated treatment that may include both an antidepressant and an antipsychotic, or another specialist intervention. It is a specific clinical presentation, and readers should not infer it merely from the intensity of sadness. NICE NG222, psychotic depression recommendations.
Electroconvulsive therapy (ECT) may be considered when rapid response is needed in life-threatening severe depression, when other treatments have been unsuccessful, or under other carefully assessed circumstances. It takes place under medical supervision and anesthesia, with informed discussion of benefits, cognitive adverse effects, and alternative options. Repetitive transcranial magnetic stimulation (rTMS) is another clinician-delivered intervention considered for selected patients, especially after inadequate response to usual care. These are not routine interchangeable steps for every person with a high questionnaire score. NICE NG222, ECT and TMS sections; NIMH.
Ketamine- and esketamine-based approaches, where licensed and clinically appropriate, belong to specialized treatment pathways with defined eligibility, monitoring, and safety requirements. Severity alone does not establish eligibility, and treatment-resistant depression has a different meaning from simply having a severe episode. A specialist determines whether an adequate course of standard treatment has occurred, considers alternative diagnoses and coexisting problems, and explains benefits and risks before an advanced intervention. VA/DoD guideline.
IX. Safety can change the plan at any severity
Clinical urgency is not a synonym for symptom score. Suicidal thoughts, a specific plan or intent, inability to meet essential needs, a rapidly deteriorating condition, severe agitation, confusion, or psychotic experiences may require urgent assessment. A person who appears organized or continues working can still face serious risk. Clinicians therefore assess safety directly instead of relying on whether depression was labeled mild or moderate. NIMH warning signs; NICE NG222.
If there is immediate danger, call emergency services or go to the nearest emergency department. In the United States, call or text 988 to reach the Suicide & Crisis Lifeline, and call 911 for a life-threatening emergency. People outside the United States should use their local emergency or crisis services. When safety is uncertain, seeking prompt professional evaluation is appropriate even before a full diagnostic assessment has been completed. NIMH crisis information.
The first weeks after beginning or changing treatment deserve attention. Clinicians monitor suicidal ideation, agitation, new behavioral changes, adverse effects, and treatment response. Antidepressant treatment in children, adolescents, and young adults requires particularly careful monitoring for newly emerging or worsening suicidal thoughts or behavior. No medication should be started, stopped, or rapidly changed on the basis of this article. NICE medication monitoring; NIMH treatment guidance.
X. Why clinicians check for bipolar disorder
Depressive symptoms also occur in bipolar disorders, but the diagnostic and treatment pathway differs from that for unipolar major depressive disorder. The assessment should ask about any past periods of abnormally elevated or irritable mood accompanied by increased energy or activity, reduced need for sleep, unusually rapid speech, increased goal-directed behavior, impulsive risk taking, or other signs of hypomania or mania. A person may present for help only during depression and never volunteer a previous elevated episode unless asked.
Identifying past mania, hypomania, or mixed features is clinically significant because antidepressant decisions and ongoing treatment may change. A depressive episode should not automatically be classified as unipolar simply because sadness or low motivation is the most visible current symptom. The comprehensive evaluation also considers family history, medication effects, and the possibility of substance-induced mood changes. VA/DoD major depressive disorder guideline; NIMH depression overview.
XI. Severity is different from depressive subtype and diagnostic specifier
Mild, moderate, and severe refer to the severity of a current episode. Other terms describe the disorder’s duration, course, associated features, or pattern. Major depressive disorder is a diagnosis. A major depressive episode is an episode of symptoms meeting specified criteria, which can occur in different diagnostic contexts. Persistent depressive disorder concerns chronic depressive symptom patterns and is assessed separately. Recurrence describes the appearance of a new episode following an interval of recovery. None of these distinctions is adequately captured by a single symptom total. WHO ICD-11 classification.
Seasonal pattern, melancholic features, atypical features, and psychotic features refer to recognized ways in which depressive presentations may be specified, depending on the diagnostic system and applicable criteria. Seasonal affective disorder is a commonly used descriptive phrase for depression with a seasonal pattern, rather than a separate severity tier. Melancholic and atypical features may help describe symptom configuration and inform clinical thinking; psychotic features substantially affect assessment and treatment. WHO ICD-11 clinical descriptions; NICE NG222.
“High-functioning depression” and “smiling depression” are popular descriptive expressions, not distinct diagnoses in DSM or ICD classifications. They may refer to someone who maintains an outward appearance of competence or cheerfulness while experiencing depressive symptoms. These labels provide little reliable information about episode severity, diagnostic eligibility, or safety. The appropriate response is to assess symptoms and functioning directly. WHO ICD-11.
XII. Why first treatment and later treatment are different decisions
The initial treatment plan reflects baseline severity, clinical safety, preferences, comorbidity, and prior history. Later decisions depend on actual response, adverse effects, adherence, access barriers, and whether the working diagnosis still fits. If symptoms have improved only partially, clinicians may adjust the current treatment, intensify psychotherapy, introduce or change medication, or refer for specialist review. A limited early response warrants a planned review rather than an automatic conclusion that treatment has failed. NICE NG222, further-line treatment.
Response usually means a meaningful reduction in symptoms; remission means symptoms have diminished to the point of minimal or absent active syndrome by the relevant clinical criteria. Recovery also concerns the return of everyday functioning and personally valued activities. Relapse refers to a return of symptoms during the course of recovery, whereas recurrence generally refers to a new episode after a period of recovery. Severity may be reassigned as the current episode changes, while a history of recurrence continues to matter for treatment planning. NICE NG222, relapse prevention.
People who have improved on antidepressants generally continue treatment for a period after symptoms remit, with individualized discussion of recurrence risk, adverse effects, and preferences. Stopping can produce withdrawal symptoms, particularly if done abruptly; a clinician-guided plan for tapering is preferable when discontinuation is appropriate. Persistent symptoms also require checking whether the person received a sufficient treatment trial and whether an unrecognized medical or psychiatric condition could explain the result. NICE NG222, starting and stopping medication.
XIII. How treatment progress should be monitored
Care begins with agreed goals that extend beyond a questionnaire score. Useful goals might include sleeping more consistently, regaining pleasure or interest, completing essential tasks, reconnecting with others, returning to study or work, or being able to care for oneself. The clinician and patient assess symptom change and functional change over time, including emerging adverse effects and concerns about safety. NICE NG222.
NICE recommends a review two to four weeks after starting treatment, with earlier or more frequent contact when clinical circumstances require it. The review considers whether the person can access the treatment, whether it is acceptable, whether symptoms are improving, and whether a change is needed. Follow-up plans may become more intensive if a person's condition worsens or self-care deteriorates, irrespective of the original severity category. NICE delivery of treatments.
A reduction in symptom severity does not erase every residual problem. Fatigue, sleep disturbance, impaired concentration, reduced social confidence, or difficult life circumstances can continue after substantial mood improvement. Continued care may address residual symptoms, functional rehabilitation, relapse prevention, and the needs the individual considers most important. VA/DoD guideline.
XIV. Severity and treatment in children and adolescents
Depression in young people requires developmentally appropriate assessment, consideration of school and family circumstances, and close attention to safety. Irritability may be more prominent than expressed sadness. Severity labels should therefore be interpreted alongside developmental context, functioning, comorbidities, and family or caregiver support where appropriate. Adult treatment pathways cannot simply be copied into pediatric care. NICE NG134.
For mild depression in children and adolescents, psychological and psychosocial interventions are generally central. NICE advises against antidepressants as initial treatment for mild depression in this age group. For moderate to severe depression, specialist review and an age-appropriate psychological treatment plan are recommended; for adolescents, individual CBT is a major first-line option and combined treatment may be considered when indicated. Medication decisions require specialist oversight, consent and monitoring appropriate to age and jurisdiction. NICE NG134, recommendations 1.5 and 1.6.
This distinction matters especially when someone asks whether a teenager with “moderate depression” should take medication. A symptom score cannot determine the answer. The decision depends on a detailed assessment, severity of impairment, safety, previous care, family circumstances, treatment availability, and the young person's preferences and developmental needs. NICE NG134.
XV. How to discuss severity with a clinician
It can help to describe concrete changes instead of trying to select a label before an appointment. A useful account covers when symptoms started, which activities have become difficult, changes in sleep and appetite, concentration and decision-making, the effect on relationships and responsibilities, prior episodes, and any treatment already tried. The person can explain what currently feels unmanageable, what support they have, and whether safety is a concern.
Questions worth discussing include: What diagnosis best explains these symptoms? How was current severity assessed? What would make treatment more intensive or urgent? Which options are supported by evidence for this presentation? What benefits and adverse effects should I expect? When will we review the plan? What should I do if symptoms worsen before that appointment? Shared decisions are a core part of modern depression care. NICE NG222.
If the assessment concludes that symptoms are mild, the plan should still specify how progress will be checked. If the conclusion is moderate or severe, the plan should explain why a particular psychotherapy, medication, combination, specialist service, or level of support is recommended. People can ask for clarification or a second professional opinion when important questions remain unanswered.
XVI. Frequently asked questions
1. Can mild depression be major depressive disorder?
Yes. Major depressive disorder describes a diagnostic condition; mild describes the current episode's severity. When the full diagnostic criteria are met, a current episode may be classified as mild. Symptoms below diagnostic threshold should be assessed separately. A diagnosis requires clinical evaluation, not a questionnaire score or self-assigned label. WHO ICD-11.
2. Is moderate depression serious?
Moderate depression can substantially disrupt functioning and warrants a meaningful treatment discussion. Its seriousness depends on the full clinical picture, including the degree of impairment, course, comorbidity, safety, and access to care. It does not mean the person must receive one specific medication or that recovery is unlikely. NICE NG222.
3. Does severe depression always require hospitalization?
No. Many people with severe depression receive intensive outpatient care. Inpatient treatment may be appropriate when safety cannot be maintained, essential needs cannot be met, or the required treatment and support cannot be delivered safely outside a hospital. The decision rests on assessment of the individual rather than the severity label alone. NICE NG222, specialist and inpatient care.
4. Is medication necessary for moderate or severe depression?
Antidepressants are a major treatment option, and combined treatment is often appropriate for more burdensome depression. However, evidence-based psychotherapy and shared decisions remain important; individual treatment choice reflects clinical need, preference, prior response, contraindications, and availability. For children and adolescents, separate age-specific recommendations apply. NICE NG222; NICE NG134.
5. Does a PHQ-9 score of 20 mean I have severe major depressive disorder?
A score of 20 falls in the conventional severe PHQ-9 symptom band. It does not independently establish major depressive disorder or provide a complete severity assessment. A clinician examines duration, diagnostic criteria, functioning, alternative explanations, and risk. Any concerns about safety need attention regardless of the total. Kroenke et al. (2001).
6. Can depression worsen from mild to severe?
Yes. Symptom intensity and daily functioning can change during an episode. Worsening symptoms, significant impairment, new psychotic features, or new safety concerns are reasons to seek prompt reassessment. Ongoing treatment monitoring is intended partly to detect such changes and adjust care. NICE NG222.
7. Can somebody with severe depression still go to work?
Sometimes. Continuing to work does not prove a depressive episode is mild, while being unable to work does not automatically determine a diagnosis. Clinicians assess the full pattern of symptoms, functioning across contexts, and safety. Outward performance cannot substitute for an interview. NICE NG222.
8. Is severe depression the same as treatment-resistant depression?
No. Severe depression describes the current clinical presentation. Treatment resistance refers to insufficient benefit from adequately delivered prior interventions, according to the definition being used. Someone may have a severe first episode before any treatment has been attempted; another person may have less dramatic current symptoms after several unsuccessful treatment trials. The treatment history must be assessed separately. VA/DoD.
9. What if symptoms are below the threshold for major depression?
Subthreshold depressive symptoms can still cause distress and affect functioning. Clinicians examine the reasons for the symptoms, monitor their course, assess risk, and discuss appropriate care. A person does not need to prove they meet major depressive disorder criteria before asking for help. NICE NG222.
10. Which treatment is best for mild, moderate, or severe depression?
There is no universal treatment assignment based only on a severity word. Mild and other less severe presentations often start with evidence-based, less intensive psychological options and planned follow-up. Moderate and severe presentations more frequently lead to formal psychotherapy, antidepressants, combined care, specialist assessment, or enhanced support. Patient preferences, age, risk, functioning, past response, and access determine the best individual plan. NICE NG222; NIMH.
Conclusion
The practical value of the mild, moderate, and severe distinction is that it helps clinicians match care to present needs and revise treatment when those needs change. The assessment integrates the depressive syndrome with functioning, duration, previous episodes, coexisting conditions, treatment history, safety, and the person's goals. Psychotherapy, medication, combined treatment, structured support, and specialist services each have a role when selected for the right clinical circumstances. A clearly agreed follow-up plan is as important as the initial category. NICE NG222; VA/DoD.
Related Articles
Depression: Symptoms, Causes, Diagnosis, and Treatment — Broad overview of major depressive symptoms, causes, diagnosis, and treatment.
Depression Diagnosis: What a Clinical Evaluation Includes — How clinicians evaluate episodes, functioning, risk, and differential diagnoses.
Depression Treatment: Therapy, Medication, and Other Options — Treatment selection and ongoing decision-making across different clinical situations.
References
American Psychological Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts: Information for patients and families.
Cuijpers, P., et al. (2023). Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: A comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry, 22, 105–115. https://doi.org/10.1002/wps.21069.
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16, 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x.
National Institute for Health and Care Excellence. (2019; updated). Depression in children and young people: Identification and management (NG134). https://www.nice.org.uk/guidance/ng134/chapter/Recommendations.
National Institute for Health and Care Excellence. (2022; updated). Depression in adults: Treatment and management (NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations.
National Institute of Mental Health. (n.d.). Depression. https://www.nimh.nih.gov/health/publications/depression.
National Institute of Mental Health. (2025). Warning signs of suicide. https://www.nimh.nih.gov/health/publications/warning-signs-of-suicide.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2022). VA/DoD clinical practice guideline for the management of major depressive disorder. https://www.healthquality.va.gov/guidelines/MH/mdd/.
World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. https://www.who.int/publications/i/item/9789240077263/.